BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 12685503)

  • 1. In vitro effects of tacrolimus on human cytochrome P450.
    Lecointre K; Furlan V; Taburet AM
    Fundam Clin Pharmacol; 2002 Dec; 16(6):455-60. PubMed ID: 12685503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro metabolism of the calmodulin antagonist DY-9760e (3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate) by human liver microsomes: involvement of cytochromes p450 in atypical kinetics and potential drug interactions.
    Tachibana S; Fujimaki Y; Yokoyama H; Okazaki O; Sudo K
    Drug Metab Dispos; 2005 Nov; 33(11):1628-36. PubMed ID: 16049129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes.
    Yao HT; Chang YW; Lan SJ; Chen CT; Hsu JT; Yeh TK
    Life Sci; 2006 Nov; 79(26):2432-40. PubMed ID: 16978661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib.
    Uttamsingh V; Lu C; Miwa G; Gan LS
    Drug Metab Dispos; 2005 Nov; 33(11):1723-8. PubMed ID: 16103134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.
    Wen X; Wang JS; Backman JT; Kivistö KT; Neuvonen PJ
    Drug Metab Dispos; 2001 Nov; 29(11):1359-61. PubMed ID: 11602509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man.
    Venkatakrishnan K; von Moltke LL; Duan SX; Fleishaker JC; Shader RI; Greenblatt DJ
    J Pharm Pharmacol; 1998 Mar; 50(3):265-74. PubMed ID: 9600717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of single-dose disulfiram effects on cytochrome P-450 2C9, 2C19, 2D6, and 3A4 activities: evidence for specificity toward P-450 2E1.
    Kharasch ED; Hankins DC; Jubert C; Thummel KE; Taraday JK
    Drug Metab Dispos; 1999 Jun; 27(6):717-23. PubMed ID: 10348802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition.
    Sahi J; Black CB; Hamilton GA; Zheng X; Jolley S; Rose KA; Gilbert D; LeCluyse EL; Sinz MW
    Drug Metab Dispos; 2003 Apr; 31(4):439-46. PubMed ID: 12642470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes.
    Lim HK; Duczak N; Brougham L; Elliot M; Patel K; Chan K
    Drug Metab Dispos; 2005 Aug; 33(8):1211-9. PubMed ID: 15860655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes.
    Wen X; Wang JS; Neuvonen PJ; Backman JT
    Eur J Clin Pharmacol; 2002 Jan; 57(11):799-804. PubMed ID: 11868802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro metabolism and drug interaction potential of a new highly potent anti-cytomegalovirus molecule, CMV423 (2-chloro 3-pyridine 3-yl 5,6,7,8-tetrahydroindolizine I-carboxamide).
    Bournique B; Lambert N; Boukaiba R; Martinet M
    Br J Clin Pharmacol; 2001 Jul; 52(1):53-63. PubMed ID: 11453890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing higher throughput methods to assess drug-drug interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6, and CYP3A4 in vitro using a single point IC(50).
    Gao F; Johnson DL; Ekins S; Janiszewski J; Kelly KG; Meyer RD; West M
    J Biomol Screen; 2002 Aug; 7(4):373-82. PubMed ID: 12230892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase.
    Grimm SW; Dyroff MC
    Drug Metab Dispos; 1997 May; 25(5):598-602. PubMed ID: 9152599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polysaccharide peptides from Coriolus versicolor competitively inhibit model cytochrome P450 enzyme probe substrates metabolism in human liver microsomes.
    Yeung JH; Or PM
    Phytomedicine; 2012 Mar; 19(5):457-63. PubMed ID: 22305191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitory effects of sanguinarine on human liver cytochrome P450 enzymes.
    Qi XY; Liang SC; Ge GB; Liu Y; Dong PP; Zhang JW; Wang AX; Hou J; Zhu LL; Yang L; Tu CX
    Food Chem Toxicol; 2013 Jun; 56():392-7. PubMed ID: 23500771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of human cytochrome P450 isoforms involved in the metabolism of S-2-[4-(3-methyl-2-thienyl)phenyl]propionic acid.
    Taguchi K; Konishi T; Nishikawa H; Kitamura S
    Xenobiotica; 1999 Sep; 29(9):899-907. PubMed ID: 10548450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen.
    Koenigs LL; Peter RM; Thompson SJ; Rettie AE; Trager WF
    Drug Metab Dispos; 1997 Dec; 25(12):1407-15. PubMed ID: 9394031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human cytochrome p450 enzymes of importance for the bioactivation of methyleugenol to the proximate carcinogen 1'-hydroxymethyleugenol.
    Jeurissen SM; Bogaards JJ; Boersma MG; ter Horst JP; Awad HM; Fiamegos YC; van Beek TA; Alink GM; Sudhölter EJ; Cnubben NH; Rietjens IM
    Chem Res Toxicol; 2006 Jan; 19(1):111-6. PubMed ID: 16411663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).
    Wen X; Wang JS; Kivistö KT; Neuvonen PJ; Backman JT
    Br J Clin Pharmacol; 2001 Nov; 52(5):547-53. PubMed ID: 11736863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation.
    Butler AM; Murray M
    J Pharmacol Exp Ther; 1997 Feb; 280(2):966-73. PubMed ID: 9023313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.